Spruce Biosciences is conducting two clinical trials evaluating its wholly-owned candidate, tildacerfont, a CRF1 receptor antagonist, for the treatment of adults with classic congenital adrenal hyperplasia (CAH). Spruce has also initiated a Phase 2 trial in pediatric patients with classic CAH.

The CAHmelia clinical trials evaluating tildacerfont in adults with classic CAH are open for screening. To learn more, and see if you may qualify, please visit sprucebio.com/cahmelia.

Spruce is also evaluating tildacerfont to reduce the production of androgens (male hormones) by the adrenal glands to help improve the health of women with Polycystic Ovary Syndrome (PCOS). To learn more about the P.O.W.E.R. study, and see if you may qualify, please visit: www.pcospowerstudy.com.

For more information on the ongoing trials in adult and pediatric patients with classic CAH, and in women with PCOS, please visit clinicaltrials.gov